Skip to main content
main-content
Top

08-01-2019 | Cutaneous T-cell lymphoma | Brief review | Article

Emerging therapies for cutaneous T-cell lymphoma

Authors:
Dawn Queen, Adriana Lopez, Larisa J Geskin

Disclosures

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of T-lymphocyte malignancies that primarily present in the skin. Mycosis fungoides (MF), the most common subtype of CTCL, presents as erythematous patches and plaques with indolent clinical behavior. Occasionally, disease may progress to tumors, and nodal or visceral involvement. Sézary syndrome (SS), the leukemic form of CTCL, presents as erythroderma – often with severe pruritus. Clinical staging is based on the skin involvement (tumor), node, metastasis, and blood (TNMB) system and more advanced stages are associated with poorer prognosis [1]. Initial workup for patients with suspected MF/SS requires skin biopsy, which is the gold standard for diagnosis. Evaluation of the biopsies may include immunophenotyping and evaluation for clonal T-cell receptor gene rearrangements. Additional staging procedures may include peripheral blood flow cytometry, imaging, and, in rare cases, bone marrow biopsy. 

Mycosis Fungoides and Sezary Syndrome © Springer International Publishing Switzerland 2015Clinical presentation of a) mycosis fungoides and b) Sézary Syndrome. Reproduced from © Springer International Publishing Switzerland 2015. Carter J.B., Goyal A. & McDivitt Duncan L. (eds) Atlas of Cutaneous Lymphomas. 10.1007/978-3-319-17217-0

The CTCL treatment landscape

To date, the only curative treatment for CTCL is allogeneic bone marrow transplantation, which is only suitable for a small subset of patients. Therefore, treatment is instead focused on symptomatic management. Choice of treatment is based on the subtype of CTCL and stage of disease at diagnosis [2]. Treatments can be divided into skin-directed therapies (SDTs) and systemic therapies. 

Early stage CTCL

For early-stage disease, SDTs are first-line options, and the mainstays of treatment include corticosteroids, ultraviolet light therapy, topical bexarotene gel (Targretin® gel), and topical mechlorethamine gel (nitrogen mustard gel; Valchlor®) (Table 1). Topical steroids and UV light therapy are common therapies for MF, used off-label for this indication. Topical bexarotene gel was FDA-approved in 2000 for refractory or persistent early-stage CTCL and had a response rate (RR) of 54% in early stage disease [3]. Mechlorethamine gel was FDA-approved a decade later in 2013 after the gel was found to have a CAILS RR of 60%, comparable to the ointment formulation in a non-inferiority trial [4]. Mechlorethamine and bexarotene gels have not been compared head-to-head in a randomized clinical trial.

Investigational medications for early stage CTCL

Numerous topical agents are currently under investigation for early stage CTCL, and results are pending from these clinical trials.

Table 1: Early stage agents. Agents available or currently under investigation for treatment of early stage CTCL (Stages IA–IIA).

Early stage (IA–IIA) agents

Mechanism of action

Phase of development

Topical bexarotene gel 1% (Targretin® gel)

Selectively binds with and activates retinoid X receptors

FDA approved in 2000 [3]

Mechlorethamine gel 0.016% (Nitrogen mustard gel; Valchlor®)

Inhibits rapidly proliferating cells

FDA approved in 2013 [4]

Topical resiquimod

Stimulates Toll-like receptor 7/8

Phase I trial

Photoactivated synthetic hypericin (SGX301)

Thought to possess significant antiproliferative effects against malignant T cells

Phase III trial

Remetinostat gel

Inhibits HDAC

Phase II trial [6]

Microneedle array-doxorubicin (MNA-D)

Delivers doxorubicin directly to cutaneous lesions

Phase I trial

Advanced-stage CTCL

Advanced disease is usually treated with systemic therapies in conjunction with SDTs for symptomatic relief (Table 2). Systemic therapies can be divided by class and mechanism of action, and can be used as monotherapies or in combination [8]. There are limited effective and durable treatment options for patients with advanced disease, and a lack of controlled trials comparing the different agents head-to-head. FDA-approved agents include oral bexarotene (Targretin®)[9], denileukin difitox (ONTAK®) [10], extracorporeal photopheresis (ECP; THERAKOS® CELLEX® Photopheresis System) [11], and HDAC inhibitors  such as vorinostat (Zolinza®) [12] and romidepsin (Istodax®) [13], among others.

In 2009, the chemotherapeutic agent pralatrexate (Folotyn®), an antimetabolite folate analog, was approved by the FDA for the treatment of patients with peripheral TCL. Compendial approval for transformed MF was granted based on findings from the  PROPEL study, which showed an objective RR in the transformed mycosis fungoides subgroup of 25% (n=3) per independent central review and 58% (n=7) per investigator assessment [14].

More recently, the antibody-drug conjugate brentuximab vedotin (Adcetris®), which targets CD30+ cells in CTCL, was approved. Approval was based on results from the phase III  ALCANZA trial, in which brentuximab vedotin demonstrated superior efficacy to standard-of-care therapy such as methotrexate or bexarotene, with durable responses [15].

In 2018, mogamulizumab (Poteligeo®), a humanized immunoglobulin G1 monoclonal antibody that targets the C-C chemokine receptor 4 (CCR4) expressed on CTCL cells [16], was approved for MF and SS patients who have received at least one prior systemic therapy. The results from a pivotal phase III study showed that mogamulizumab reduced the risk of progression or death by 47% compared with vorinostat [17].

Investigational medications for advanced stage CTCL

A multitude of therapies with novel mechanisms of action as well as new combinations are also being investigated in ongoing clinical trials for advanced-stage CTCL.

Importantly, the genetic classification of CTCL was recently created by compiling and analyzing raw data from 139 CTCL cases from seven deep-sequencing studies of MF and SS [18]. Analysis revealed significant mutual exclusivity of mutations and disrupted pathways in CTCL. Importantly, in SS, mutually exclusive mutations occur in the NFkB pathway genes PLCG1, CARD11, TNFRSF1B, and KIT. This has important therapeutic implications as it suggests that selective targeting of patient-specific mutations may direct future therapy. That is, agents like proteasome inhibitors or JAK inhibitors that target specific pathways may be optimally used in specific subsets of patients. Further tests are needed to validate this genetic classification system as a tool for guiding future therapy.

Table 2: Advanced-stage agents. Agents available or currently under investigation for treatment of advanced stage CTCL (Stages IIB–SS).

Advanced-stage (IIB–SS) agents

Mechanism of action

Phase of development

Oral bexarotene (Targretin®)

Selectively activates retinoid X receptors

FDA approved in 1999 [9]

Denileukin difitox (ONTAK®)

Directs the cytocidal action of diphtheria toxin to cells that express the IL-2 receptor

FDA approved in 1999 [10]

Extracorporeal photopheresis (ECP; THERAKOS® CELLEX® Photopheresis System)

Treats extracorporeally circulating leukocytes with UVA activated psoralen

FDA approved in 1998 [11]

Vorinostat (Zolinza®)

HDAC inhibitor

FDA approved in 2006 [12]

Romidepsin (depsipeptide; FK228; Istodax®)

HDAC inhibitor

FDA approved in 2009 [13]

Pralatrexate (Folotyn®)

Inhibits dihydrofolate reductase

FDA approved in 2009 for transformed MF [14]

Brentuximab vedotin (Adcetris®)

Targets CD30

FDA approved in 2017 [15]

Mogamulizumab (Poteligeo®)

Targets CCR4

FDA approved in 2018 [17]

Pembrolizumab (Keytruda®)

PD-1 checkpoint inhibitor

Phase II Trial [19]

Bortezomib (Velcade®)

Proteasome inhibitor

Phase II trial [22]

Marizomib (MRZ, NPI-0052)

Second generation proteasome inhibitor

Phase I trial

Cobomarsen (MRG-106)

Inhibitor of microRNA-155 which is thought to promote malignant T cell proliferation

Phase I trial

Lenalidomide (CC-5013, Revlimid®)

Immunomodulatory activity

Phase II trial [27]

Ruxolitinib (Jakafi®)

JAK inhibitor

Phase II trial

AFM13

Recruits NK cells via binding to CD16A as immune effector cells

Phase IB/IIA trial

Talimogene laherparepvec (T-VEC, Imlygic™)

Stimulates antitumor immune response

Phase II trial

Conclusion

CTCL is a challenging disease to treat, and current therapy focuses on preventing progression rather than curing the disease completely. The number of available treatments has increased in recent years and the future is promising as yet more new classes of drugs and novel mechanisms of delivery are being explored. In particular, the development of the genetic classification system for CTCL may allow for selective targeting of therapy to patient-specific mutations.

Literature

Related topics

Image Credits